| Literature DB >> 33239886 |
Shesh Narayan Kandel1, Nabaraj Adhikari2, Binod Dhungel2, Upendra Thapa Shrestha2, Khadga Bikram Angbuhang1, Gayatri Karki3, Bipin Adhikari4, Megha Raj Banjara2, Komal Raj Rijal2, Prakash Ghimire2.
Abstract
INTRODUCTION: Methicillin resistant Staphylococcus aureus (MRSA) is a major human pathogen associated with nosocomial and community infections. mecA gene is considered one of the important virulence factors of S. aureus responsible for acquiring resistance against methicillin. The main objective of this study was to explore the prevalence, antibiotic susceptibility pattern, and mec A gene.Entities:
Keywords: MRSA; Staphylococcus aureus; cefoxitin; mecA gene
Year: 2020 PMID: 33239886 PMCID: PMC7675858 DOI: 10.1177/1178636120972695
Source DB: PubMed Journal: Microbiol Insights ISSN: 1178-6361
Figure 1.Distribution of bacterial genera among culture positive clinical specimens.
Distribution of S. aureus and MRSA in clinical specimens and according to age group, gender, and type of patients.
| Characters | Bacterial growth |
| MRSA | ||
|---|---|---|---|---|---|
| Clinical specimens | |||||
| Urine | 90 (58.9) | 9 (23. 1) | 4 (22.2) | ||
| Blood | 20 (13.1) | 4 (10.2) | 2 (11.1) | ||
| Wound swab | 25 (16.3) | 16 (41.1) | 7(38.8) | ||
| Pus | 15 (9.8) | 8 (20.5) | 4 (22.2) | ||
| Body fluid | 3 (1.9) | 2 (5.1) | 1(5.5) | ||
| Total | 153 | 39 | 18 | ||
| Age group in years | |||||
| <14 | 10 (25.6) | .9 | 2 (11.1) | .31 | |
| (15-45) | 21 (53.8) | 12 (66.7) | |||
| >45 | 8 (20.6) | 4 (22.2) | |||
| Gender | |||||
| Male | 22 (56.4) | .08 | 11 (61.1) | .11 | |
| Female | 17 (43.6) | 7 (38.9) | |||
| Type of patients | |||||
| Inpatients | 23 (59) | .001 | 13 (72.2) | .002 | |
| Outpatients | 16 (41) | 5 (27.8) | |||
Antibiotic susceptibility pattern of S. aureus and MRSA.
| Antibiotics | MRSA (n = 18) | |||
|---|---|---|---|---|
| Sensitive N (%) | Resistant N (%) | Sensitive N (%) | Resistant N (%) | |
| Gentamycin | 28 (71.8) | 11(28.2) | 10 (55.5) | 8 (44.5) |
| Amikacin | 33 (84.6) | 6 (15.4) | 15 (83.3) | 3 (16.7) |
| Amoxicillin | 4 (10.3) | 35 (89.7) | 0 (0) | 18 (100) |
| Cefoxitin | 21 (53.9) | 18 (46.1) | 0 (0) | 18 (100) |
| Meropenem | 30 (76.9) | 9 (23.1) | 9 (50) | 9 (50) |
| Vancomycin | 39 (100) | 0 (0) | 18 (100) | 0 (0) |
| Erythromycin | 26 (66.7) | 13 (33.3) | 5 (27.8) | 13 (72.2) |
| Chloramphenicol | 31 (79.5) | 8 (20.5) | 8 (44.5) | 10 (55.5) |
| Ciprofloxacin | 25 (64.1) | 14 (35.9) | 5 (27.8) | 13 (72.2) |
| Cotrimoxazole | 14 (35.9) | 25 (64.1) | 3 (16.7) | 15 (83.3) |
| Tetracycline | 20 (51.3) | 19 (48.7) | 5 (27.8) | 13 (72.2) |
Figure 2.Visualization of amplified mecA gene under UV Trans-illuminator.
Abbreviations: L1, NEB 100 bp DNA marker; L2, Negative control S. aureus ATCC 29213; L3, Positive control S. aureus ATCC 49476; L4-L10, different clinical S. aureus isolates).